There are 2137 resources available
239P - Impact of clinical characteristics, patients' perception of treatment goals and endocrine therapy history on HRQOL in HR+, HER2- early stage breast cancer patients
Presenter: Rhys Williams
Session: E-Poster Display
Resources:
Abstract
240P - A multinational real-world study on HR+, HER2- early stage breast cancer patients' disease awareness, satisfaction, and involvement in treatment decisions
Presenter: Alex Rider
Session: E-Poster Display
Resources:
Abstract
241P - Germline genetic features of Chinese patients with breast cancer
Presenter: Manming Cao
Session: E-Poster Display
Resources:
Abstract
242P - Reclassification of variants of unknown significance in BRCA 1/2 genes for the improvement of care quality in oncological genetic council units
Presenter: Alejandro Olivares Hernandez
Session: E-Poster Display
Resources:
Abstract
243P - UK experience of the management of pregnancy associated breast cancer: A national retrospective review of practice
Presenter: Emily Goode
Session: E-Poster Display
Resources:
Abstract
244P - Breast cancer in young women (BCYW): Real world data to fill the gap and find the needs
Presenter: Mariola Blanco Clemente
Session: E-Poster Display
Resources:
Abstract
245P - Breast cancer in young women (BCYW): Clinical impact of diagnosis in asymptomatic patients
Presenter: Miriam Mendez Garcia
Session: E-Poster Display
Resources:
Abstract
246P - A survey of breast cancer patients’ attitudes toward the breast reconstruction based on breast implant associated-anaplastic large cell lymphoma (BIA-ALCL)
Presenter: Hitomi Suzuki
Session: E-Poster Display
Resources:
Abstract
247P - Population-based testing for hereditary breast and ovarian cancer in a cohort of 1,346 patients from Southern Italy (Sicily): When historical background affects genetics
Presenter: Daniele Fanale
Session: E-Poster Display
Resources:
Abstract
248TiP - A randomized, double-blind, phase III trial of neoadjuvant chemotherapy (NACT) with atezolizumab/placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant continuation of atezolizumab/placebo (GeparDouze)
Presenter: Sibylle Loibl
Session: E-Poster Display
Resources:
Abstract